ASX - By Stock
|
CYP |
Re:
Ann: Cynata to Acquire IP from Tekcyte
|
|
lenzj010
|
73 |
16K |
1 |
01/07/24 |
01/07/24 |
ASX - By Stock
|
73
|
16K
|
1
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Initial Results in First 16 DFU Patients Expected in Q1 2024
|
|
lenzj010
|
37 |
13K |
7 |
08/02/24 |
08/02/24 |
ASX - By Stock
|
37
|
13K
|
7
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Initial Results in First 16 DFU Patients Expected in Q1 2024
|
|
lenzj010
|
37 |
13K |
11 |
02/02/24 |
02/02/24 |
ASX - By Stock
|
37
|
13K
|
11
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Initial Results in First 16 DFU Patients Expected in Q1 2024
|
|
lenzj010
|
37 |
13K |
3 |
10/01/24 |
10/01/24 |
ASX - By Stock
|
37
|
13K
|
3
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Phase 3 Osteoarthritis Clinical Trial Commences
|
|
lenzj010
|
394 |
87K |
5 |
12/12/23 |
12/12/23 |
ASX - By Stock
|
394
|
87K
|
5
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Phase 2 Trial of CYP-001 in aGvHD Approved in Turkey
|
|
lenzj010
|
9 |
3.0K |
4 |
08/12/23 |
08/12/23 |
ASX - By Stock
|
9
|
3.0K
|
4
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Top 20 Listed Optionholders & Distribution Schedule
|
|
lenzj010
|
15 |
6.0K |
0 |
01/06/23 |
01/06/23 |
ASX - By Stock
|
15
|
6.0K
|
0
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Two-Year Results of Phase 1 SR-aGvHD Trial Presented at ISCT
|
|
lenzj010
|
56 |
16K |
5 |
26/05/23 |
26/05/23 |
ASX - By Stock
|
56
|
16K
|
5
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Capital Raising Presentation
|
|
lenzj010
|
226 |
57K |
1 |
25/04/23 |
25/04/23 |
ASX - By Stock
|
226
|
57K
|
1
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Capital Raising Presentation
|
|
lenzj010
|
226 |
57K |
1 |
24/04/23 |
24/04/23 |
ASX - By Stock
|
226
|
57K
|
1
|
|
ASX - By Stock
|
CYP |
Disallowed (reverse)
|
|
lenzj010
|
3 |
1.2K |
11 |
18/04/23 |
18/04/23 |
ASX - By Stock
|
3
|
1.2K
|
11
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Capital Raising Presentation
|
|
lenzj010
|
226 |
57K |
7 |
18/04/23 |
18/04/23 |
ASX - By Stock
|
226
|
57K
|
7
|
|
ASX - By Stock
|
CMB |
Re:
Ann: Notice of Termination of Kyocera Licence
|
|
lenzj010
|
34 |
17K |
0 |
31/01/23 |
31/01/23 |
ASX - By Stock
|
34
|
17K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
MSB All-time low Party Thread
|
|
lenzj010
|
396 |
110K |
4 |
03/07/22 |
03/07/22 |
ASX - By Stock
|
396
|
110K
|
4
|
|
ASX - By Stock
|
CYP |
Re:
Ann: FDA Clears Cynata IND for Phase 2 Trial in GvHD
|
|
lenzj010
|
73 |
23K |
1 |
26/05/22 |
26/05/22 |
ASX - By Stock
|
73
|
23K
|
1
|
|
ASX - By Stock
|
CYP |
Trading
|
|
lenzj010
|
0 |
394 |
9 |
07/03/22 |
07/03/22 |
ASX - By Stock
|
0
|
394
|
9
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Appendix 3Y- Dr Stewart Washer
|
|
lenzj010
|
18 |
4.8K |
4 |
02/12/21 |
02/12/21 |
ASX - By Stock
|
18
|
4.8K
|
4
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
lenzj010
|
10K |
3.0M |
1 |
20/09/21 |
20/09/21 |
ASX - By Stock
|
10K
|
3.0M
|
1
|
|
Charts
|
CYP |
Re:
CYP chart
|
|
lenzj010
|
1.9K |
600K |
19 |
11/08/21 |
11/08/21 |
Charts
|
1.9K
|
600K
|
19
|
|
ASX - By Stock
|
CYP |
Re:
Ann: First Patient Enrolled in Cynata MEND Clinical Trial
|
|
lenzj010
|
183 |
38K |
5 |
06/08/21 |
06/08/21 |
ASX - By Stock
|
183
|
38K
|
5
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Cynata Appoints Dr Jolanta Airey Chief Medical Officer
|
|
lenzj010
|
13 |
4.4K |
8 |
26/07/21 |
26/07/21 |
ASX - By Stock
|
13
|
4.4K
|
8
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Fujifilm Exercises License Option in GvHD
|
|
lenzj010
|
327 |
127K |
9 |
06/06/21 |
06/06/21 |
ASX - By Stock
|
327
|
127K
|
9
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Cynata signs Licence Agreement with TekCyte
|
|
lenzj010
|
58 |
12K |
12 |
03/06/21 |
03/06/21 |
ASX - By Stock
|
58
|
12K
|
12
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Cynata signs Licence Agreement with TekCyte
|
|
lenzj010
|
58 |
12K |
9 |
03/06/21 |
03/06/21 |
ASX - By Stock
|
58
|
12K
|
9
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Cynata Expands trial in COVID-19 & Respiratory Failure
|
|
lenzj010
|
221 |
51K |
11 |
22/05/21 |
22/05/21 |
ASX - By Stock
|
221
|
51K
|
11
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Quarterly Activity Report & Appendix 4C
|
|
lenzj010
|
99 |
21K |
4 |
30/04/21 |
30/04/21 |
ASX - By Stock
|
99
|
21K
|
4
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Quarterly Activity Report & Appendix 4C
|
|
lenzj010
|
99 |
21K |
5 |
28/04/21 |
28/04/21 |
ASX - By Stock
|
99
|
21K
|
5
|
|
ASX - By Stock
|
CYP |
Re:
CYP 2021 - The year ahead
|
|
lenzj010
|
465 |
104K |
12 |
22/04/21 |
22/04/21 |
ASX - By Stock
|
465
|
104K
|
12
|
|
ASX - By Stock
|
CYP |
Re:
Did you HODL?
|
|
lenzj010
|
67 |
17K |
10 |
17/03/21 |
17/03/21 |
ASX - By Stock
|
67
|
17K
|
10
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Cynata Investor Presentation
|
|
lenzj010
|
31 |
8.8K |
13 |
12/03/21 |
12/03/21 |
ASX - By Stock
|
31
|
8.8K
|
13
|
|
ASX - By Stock
|
CYP |
Re:
Did you HODL?
|
|
lenzj010
|
67 |
17K |
16 |
02/03/21 |
02/03/21 |
ASX - By Stock
|
67
|
17K
|
16
|
|
ASX - By Stock
|
CYP |
Did you HODL?
|
|
lenzj010
|
67 |
17K |
12 |
26/02/21 |
26/02/21 |
ASX - By Stock
|
67
|
17K
|
12
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Cynata Receives $1.39m R&D Tax Incentive Refund
|
|
lenzj010
|
76 |
14K |
1 |
24/02/21 |
24/02/21 |
ASX - By Stock
|
76
|
14K
|
1
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Cynata Receives $1.39m R&D Tax Incentive Refund
|
|
lenzj010
|
76 |
14K |
6 |
22/02/21 |
22/02/21 |
ASX - By Stock
|
76
|
14K
|
6
|
|
ASX - By Stock
|
CYP |
Re:
CYP 2021 - The year ahead
|
|
lenzj010
|
465 |
104K |
5 |
12/02/21 |
12/02/21 |
ASX - By Stock
|
465
|
104K
|
5
|
|
ASX - By Stock
|
CYP |
Re:
CYP 2021 - The year ahead
|
|
lenzj010
|
465 |
104K |
11 |
05/02/21 |
05/02/21 |
ASX - By Stock
|
465
|
104K
|
11
|
|
ASX - By Stock
|
CYP |
Re:
CYP 2021 - The year ahead
|
|
lenzj010
|
465 |
104K |
13 |
03/02/21 |
03/02/21 |
ASX - By Stock
|
465
|
104K
|
13
|
|
ASX - By Stock
|
CYP |
Re:
CYP 2021 - The year ahead
|
|
lenzj010
|
465 |
104K |
5 |
25/01/21 |
25/01/21 |
ASX - By Stock
|
465
|
104K
|
5
|
|
ASX - By Stock
|
CYP |
Re:
CYNATA - 2021 The Year of Multiple Trials
|
|
lenzj010
|
7 |
3.2K |
15 |
24/12/20 |
24/12/20 |
ASX - By Stock
|
7
|
3.2K
|
15
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Letter to Optionholders
|
|
lenzj010
|
237 |
35K |
1 |
15/12/20 |
15/12/20 |
ASX - By Stock
|
237
|
35K
|
1
|
|
ASX - By Stock
|
EMD |
Re:
Ready to pop
|
|
lenzj010
|
13 |
4.4K |
2 |
04/12/20 |
04/12/20 |
ASX - By Stock
|
13
|
4.4K
|
2
|
|
ASX - By Stock
|
EMD |
Re:
Ready to pop
|
|
lenzj010
|
13 |
4.4K |
2 |
04/12/20 |
04/12/20 |
ASX - By Stock
|
13
|
4.4K
|
2
|
|
ASX - By Stock
|
CYP |
Re:
Questions for the Board at the AGM 2020
|
|
lenzj010
|
88 |
18K |
2 |
02/12/20 |
02/12/20 |
ASX - By Stock
|
88
|
18K
|
2
|
|
ASX - By Stock
|
EMD |
Ready to pop
|
|
lenzj010
|
13 |
4.4K |
5 |
02/12/20 |
02/12/20 |
ASX - By Stock
|
13
|
4.4K
|
5
|
|
ASX - By Stock
|
CYP |
Re:
Mesoblast and Novartis collaboration
|
|
lenzj010
|
148 |
25K |
7 |
20/11/20 |
20/11/20 |
ASX - By Stock
|
148
|
25K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Phase 3 DREAM HF-1 read-out
|
|
lenzj010
|
344 |
181K |
5 |
31/10/20 |
31/10/20 |
ASX - By Stock
|
344
|
181K
|
5
|
|
ASX - By Stock
|
CYP |
Re:
CYP vs MSB
|
|
lenzj010
|
644 |
126K |
5 |
30/10/20 |
30/10/20 |
ASX - By Stock
|
644
|
126K
|
5
|
|
ASX - By Stock
|
CYP |
Re:
CYP vs MSB
|
|
lenzj010
|
644 |
126K |
2 |
29/10/20 |
29/10/20 |
ASX - By Stock
|
644
|
126K
|
2
|
|
ASX - By Stock
|
CYP |
Re:
CYP vs MSB
|
|
lenzj010
|
644 |
126K |
0 |
28/10/20 |
28/10/20 |
ASX - By Stock
|
644
|
126K
|
0
|
|
Charts
|
CYP |
Re:
Chart - CYP
|
|
lenzj010
|
345 |
95K |
3 |
18/08/20 |
18/08/20 |
Charts
|
345
|
95K
|
3
|
|